• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Boundless Bio Inc.

    4/29/25 4:05:02 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLD alert in real time by email
    DEFA14A 1 bold_defa14a_2025.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

    Filed by the Registrant☒

    Filed by a Party other than the Registrant☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    BOUNDLESS BIO, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

     

    img60772984_0.jpg

    LOGO BOUNDLESS BIO C/O TABULATOR P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Boundless Bio, Inc. Annual Meeting of Stockholders Monday, June 23, 2025 8:00 AM Pacific Time Annual meeting will be held via live webcast. Please visit www.proxydocs.com/BOLD for more details. You may register to attend the meeting online and/or participate at www.proxydocs.com/BOLD. For a convenient way to view proxy materials, VOTE and obtain instructions to attend the meeting go to www.proxydocs.com/BOLD. To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 13, 2025. SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Annual Meeting of Stockholders, Proxy Statement and Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 23, 2025 for stockholders of record as of April 25, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/BOLDCall: 1-866-648-8133 Email: [email protected] * If requesting materials by e-mail, please send a blank e-mail with the 12 digit control number located below in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting materials. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

     


     

     

    img60772984_1.jpg

    LOGO BOUNDLESS BIO Boundless Bio, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH NOMINEE IDENTIFIED BELOW AND FOR PROPOSAL 2 PROPOSAL 1. Election of Directors 1.01 Christine Brennan, Ph.D. 1.02 Nancy Whiting, Pharm.D. 2. Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. NOTE: Transact other business that may properly come before the meeting or any adjournment or postponement thereof.

     


    Get the next $BOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BOLD

    DatePrice TargetRatingAnalyst
    12/13/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $BOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Boundless Bio Inc.

      SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

      10/29/24 6:32:08 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Doebele Robert

      4 - Boundless Bio, Inc. (0001782303) (Issuer)

      2/3/25 6:38:53 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Doebele Robert

      3 - Boundless Bio, Inc. (0001782303) (Issuer)

      2/3/25 6:29:34 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Hassig Christian

      4 - Boundless Bio, Inc. (0001782303) (Issuer)

      1/23/25 4:05:10 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

      SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert ("Bob") Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. "We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "Bob has been a driving force behind precisio

      2/3/25 10:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BOLD
    SEC Filings

    See more
    • Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

      Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended

      5/9/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio to Participate in the Needham Virtual Healthcare Conference

      SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham's Virtual Healthcare Conference. A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website and can be accessed via this link: https://wsw.com/webcast/needham14

      4/3/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial res

      3/27/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio downgraded by Guggenheim

      Guggenheim downgraded Boundless Bio from Buy to Neutral

      12/13/24 7:26:11 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Boundless Bio Inc.

      10-Q - Boundless Bio, Inc. (0001782303) (Filer)

      5/9/25 7:10:19 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Boundless Bio, Inc. (0001782303) (Filer)

      5/9/25 7:05:23 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Boundless Bio Inc.

      DEFA14A - Boundless Bio, Inc. (0001782303) (Filer)

      4/29/25 4:05:02 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care